In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Time to medical treatment and one-year survival after an acute coronary event according to the first medical contact unit (primary care or hospital): results from the ERICO study.

Session Poster Session III - Friday 08:30 - 12:30

Speaker Assistant Professor Itamar Santos

Congress : EuroPrevent 2015

  • Topic : e-cardiology / digital health, public health, health economics, research methodology
  • Sub-topic : Public Health and Health Economics
  • Session type : Poster Session
  • FP Number : P542

Authors : I S Santos (Sao Paulo,BR), AC Goulart (Sao Paulo,BR), RCO Santos (Sao Paulo,BR), ALX Kisukuri (Sao Paulo,BR), RM Brandao (Sao Paulo,BR), D Sitnik (Sao Paulo,BR), HL Staniak (Sao Paulo,BR), MS Bittencourt (Sao Paulo,BR), PA Lotufo (Sao Paulo,BR), IM Bensenor (Sao Paulo,BR)

15 views

Authors:
I S Santos1 , AC Goulart1 , RCO Santos1 , ALX Kisukuri1 , RM Brandao1 , D Sitnik1 , HL Staniak1 , MS Bittencourt1 , PA Lotufo1 , IM Bensenor1 , 1University of Sao Paulo - Sao Paulo - Brazil ,

Citation:

Purpose: The importance of timely and efficient first medical contact (FMC) in the acute coronary syndrome (ACS) treatment is widely recognized. However, little is known about the outcomes of individuals who initially seek a primary care unit for an ACS event. The aim of the present study is to determine if FMC at primary care (PC-FMC) or at hospital (H-FMC) are determinants of time to medical treatment and/or one-year survival in the Strategy of Registry of Acute Coronary Syndrome (ERICO) study.
Methods: The ERICO study is a cohort study of individuals treated for an ACS event between 2009 and 2013 in Hospital Universitário, a community hospital in the borough of Butantã, São Paulo, Brazil. Follow-up was performed at 30 days, 180 days and one year after the index event, by telephone contact. We revised data from 701 ERICO participants (87 with PC-FMC and 614 with H-FMC). We used Wilcoxon test to determine if time from FMC to the administration of aspirin, clopidogrel and heparin (in individuals with non-ST elevation ACS) and thrombolysis (in individuals with ST-elevation ACS) was different according to the FMC unit. We built Cox regression models adjusted for age, sex and ACS subtype to study if the FMC unit predicted one-year survival in the sample.
Results: Administration of aspirin, clopidogrel and heparin was almost universal (100.0%, 97.7% and 97.7% in PC-FMC and 98.5%, 96.6% and 96.4% in H-FMC groups. Individuals with non-ST elevation ACS in the PC-FMC group received aspirin earlier than in the H-FMC group (median time, 2.40 vs 2.53 hours, p<0.001). There was also a trend towards an earlier administration of aspirin in ST-elevation ACS patients in the PC-FMC group (median time, 0.70 vs 1.13 hours, p=0.075). Time to thrombolysis in ST-elevation ACS patients was non-significantly lower in H-FMC group (median time, 1.03 vs. 1.15, p=0.19). Complete vital status data was available for 669 (95.4%) participants. We had eight (9.9%) and 67 (11.4%) deaths during follow-up in the PC-FMC and H-FMC groups, respectively. FMC unit was not a predictor for one-year survival in this sample. The adjusted hazard ratio for PC-FMC was 1.03 (95% confidence interval 0.50–2.16).
Conclusions: Our findings suggest that primary care can be a suitable setting for the evaluation of acute chest pain, once timely evaluation, safe transportation and access to hospital treatment are warranted. Respecting the characteristics of local health systems, policy makers should consider to organize such strategy for the system-of-care during a suspected ACS event.



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are